GCKR and gastric cancer: It was previously found that GCKR polymorphism may be an independent predictor of survival for metastatic GC patients receiving first-line EOF chemotherapy (epirubicin, oxaliplatin, and 5-FU combined chemotherapy) (33), which is consistent with the results of our work.